130 related articles for article (PubMed ID: 15325097)
1. Molecular genetic analysis of deep-seated glioblastomas.
Hayashi Y; Yamashita J; Watanabe T
Cancer Genet Cytogenet; 2004 Aug; 153(1):64-8. PubMed ID: 15325097
[TBL] [Abstract][Full Text] [Related]
2. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
[TBL] [Abstract][Full Text] [Related]
4. Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations.
Watanabe T; Nobusawa S; Lu S; Huang J; Mittelbronn M; Ohgaki H
J Neuropathol Exp Neurol; 2009 Feb; 68(2):210-5. PubMed ID: 19151620
[TBL] [Abstract][Full Text] [Related]
5. Amplification of the epidermal growth factor receptor gene in glioblastoma: an analysis of the relationship between genotype and phenotype by CISH method.
Miyanaga T; Hirato J; Nakazato Y
Neuropathology; 2008 Apr; 28(2):116-26. PubMed ID: 18021194
[TBL] [Abstract][Full Text] [Related]
6. Genetic analyses for predictors of radiation response in glioblastoma.
Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
[TBL] [Abstract][Full Text] [Related]
7. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations in malignant astrocytomas.
Biernat W; Debiec-Rychter M; Kordek R; Liberski PP
Pol J Pathol; 1997; 48(4):221-4. PubMed ID: 9529927
[TBL] [Abstract][Full Text] [Related]
9. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
10. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations.
Jesien-Lewandowicz E; Jesionek-Kupnicka D; Zawlik I; Szybka M; Kulczycka-Wojdala D; Rieske P; Sieruta M; Jaskolski D; Och W; Skowronski W; Sikorska B; Potemski P; Papierz W; Liberski PP; Kordek R
Cancer Genet Cytogenet; 2009 Jan; 188(2):77-82. PubMed ID: 19100509
[TBL] [Abstract][Full Text] [Related]
11. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas.
Okada Y; Hurwitz EE; Esposito JM; Brower MA; Nutt CL; Louis DN
Cancer Res; 2003 Jan; 63(2):413-6. PubMed ID: 12543796
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations in glioblastoma multiforme.
Hartmann C; Bartels G; Gehlhaar C; Holtkamp N; von Deimling A
Acta Neuropathol; 2005 Jun; 109(6):639-42. PubMed ID: 15924253
[TBL] [Abstract][Full Text] [Related]
13. Molecular pathogenesis of pediatric astrocytic tumors.
Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
[TBL] [Abstract][Full Text] [Related]
14. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick L; Wang XY; Eley G; James CD
Cancer Res; 2000 Mar; 60(5):1383-7. PubMed ID: 10728703
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival with glioblastoma multiforme.
Krex D; Klink B; Hartmann C; von Deimling A; Pietsch T; Simon M; Sabel M; Steinbach JP; Heese O; Reifenberger G; Weller M; Schackert G;
Brain; 2007 Oct; 130(Pt 10):2596-606. PubMed ID: 17785346
[TBL] [Abstract][Full Text] [Related]
16. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
[TBL] [Abstract][Full Text] [Related]
17. p53 mutation and epidermal growth factor receptor overexpression in glioblastoma.
Yoon KS; Lee MC; Kang SS; Kim JH; Jung S; Kim YJ; Lee JH; Ahn KY; Lee JS; Cheon JY
J Korean Med Sci; 2001 Aug; 16(4):481-8. PubMed ID: 11511795
[TBL] [Abstract][Full Text] [Related]
18. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
[TBL] [Abstract][Full Text] [Related]
19. Molecular genetic analysis of giant cell glioblastomas.
Meyer-Puttlitz B; Hayashi Y; Waha A; Rollbrocker B; Boström J; Wiestler OD; Louis DN; Reifenberger G; von Deimling A
Am J Pathol; 1997 Sep; 151(3):853-7. PubMed ID: 9284834
[TBL] [Abstract][Full Text] [Related]
20. p53 status has no prognostic significance in glioblastomas treated with radiotherapy.
Baxendine-Jones J; Campbell I; Ellison D
Clin Neuropathol; 1997; 16(6):332-6. PubMed ID: 9401801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
